Sort   by:  
 Page size 
UnknownLipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
Not available
S-EPMC7724642 | biostudies-literature
UnknownApixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.
Not available
S-EPMC9134037 | biostudies-literature
UnknownEffect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis.
Not available
S-EPMC7308542 | biostudies-literature
UnknownLowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants.
Not available
S-EPMC8370761 | biostudies-literature
UnknownGenomic architecture and introgression shape a butterfly radiation.
Not available
S-EPMC7197882 | biostudies-literature
UnknownThe Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges.
Not available
S-EPMC8887957 | biostudies-literature
UnknownUpregulation of Human Endogenous Retrovirus-K Is Linked to Immunity and Inflammation in Pulmonary Arterial Hypertension.
Not available
S-EPMC5685911 | biostudies-literature
UnknownSafety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Not available
S-EPMC11249957 | biostudies-literature
UnknownLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Not available
S-EPMC8822604 | biostudies-literature
UnknownGlobal Genomic Diversity of Human Papillomavirus 11 Based on 433 Isolates and 78 Complete Genome Sequences.
Not available
S-EPMC4934746 | biostudies-literature
Sort   by:  
 Page size